Compare Medline Inc. Class A Common Stock (MDLN) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medline Inc. Class A Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Medline Inc. Class A Common Stock trades at $35.74 (market cap $31.36B), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: Medline Inc. Class A Common Stock is far larger — about 18× Nuvation Bio Inc. Class A Common Stock's market cap, and Medline Inc. Class A Common Stock is more actively traded (10,191,251 versus 9,289,619). Which is the better fit depends on your goals — on Pluang, investors hold Medline Inc. Class A Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| MDLN | NUVB | |
|---|---|---|
Market Cap | $31.36B | $1.74B |
Volume | 10,191,251 | 9,289,619 |
Sector | Health | Health |
52-Week High | $49.99 | $9.54 |
52-Week Low | $31.64 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $41.32B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
